Generics 24

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Colistimethate sodium manufacturers

24 products found

Filters

24 products found

colistimethate sodium

Vials, injection 1000000 IU

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Albania , Kosovo , North Macedonia , Montenegro , Serbia , United Kingdom
Registered in
North Macedonia , Kosovo , Albania , Serbia , Montenegro
Available for
Licensing with supply, Distribution only
Manufacturer #16255
The company is a 100% Greek pharmaceutical company whose major activities are the creation and trading of branded generic pharmaceutical products while maintaining a high level of patient respect and devotion. It is the holder of more than 70 marketing authorizations for pharmaceutical products and the launcher of more than 46 of them.

Manufacturer usually replies in 8 days

colistimethate sodium

Nebuliser solution 1 MIU, 2 MIU

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP, Greece
Manufacturer #298

Manufacturer usually replies in 5 days

colistimethate sodium

Injection, lyophilized 1 MIU, 2 MIU

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP, Greece
Manufacturer #298

Manufacturer usually replies in 5 days

colistimethate sodium

Nebuliser solution 1 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Austria
Manufacturer #17277
It is a European giant with a global distribution network and overseas branch offices are also available. The company's approximately 500 employees and stable management team can look back on a more than 100-year history. PARI has been a trusted name for doctors, pharmacists, and patients for decades as a maker of medical devices with a concentration on inhalation devices.

Manufacturer usually replies in 6 days

colistimethate sodium

Nebuliser solution 80mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #570
A pharmaceutical manufacturer based in the EU that has been active in 80+ countries selling its products for 110+ years. Main therapeutic areas include CNS, respiratory, and women’s health. Main dosage forms include sterile drugs, solid oral, and liquid forms. The company owns 20+ branches in Europe, North America, and Asia. The company possesses manufacturing facilities in Europe, Asia, and LATAM.

Manufacturer usually replies in 9 days

colistimethate sodium

Nebuliser solution 1000000 IU

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
RLD-Colomycin (Forest Laboratories) (RX)
Manufacturer #19992
A pharmaceutical manufacturer based in the EU that is active in 20+ countries selling its products for 190+ years. Key production lines are Rx, OTC, medical devices, and nutraceuticals. The company's production lines are GMP-compliant. Main therapy areas include anti-infectives, dermatology, and CNS. The company products are prepared in CTD dossier format.

Manufacturer usually replies in 6 days

colistimethate sodium

Powder for solution for injection/infusion 1000000 IU

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
RLD-Colomycin (Forest Laboratories)
Manufacturer #19992
A pharmaceutical manufacturer based in the EU that is active in 20+ countries selling its products for 190+ years. Key production lines are Rx, OTC, medical devices, and nutraceuticals. The company's production lines are GMP-compliant. Main therapy areas include anti-infectives, dermatology, and CNS. The company products are prepared in CTD dossier format.

Manufacturer usually replies in 6 days

colistimethate sodium

Powder for solution for injection 1 MIU, 2 MIU - 10 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Albania , Bosnia And Herzegovina , France , Italy , Kosovo , North Macedonia , Montenegro , Portugal , Serbia , United Kingdom , Vietnam
Registered in
Belgium , France , Italy , Portugal , Spain
Available for
Licensing with supply
Comments
Country of origin- Spain and Italy
Manufacturer #15084

Manufacturer usually replies in 18 days

colistimethate sodium

Nebuliser solution 80 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Australia
GMP approvals
TGA
Unavailable markets
Russia
Manufacturer #13731
It is a European-owned company dedicated to providing training and job opportunities in the domains of research and development as well as commercial product production for both domestic and international markets. Over 65 drugs in essential therapeutic areas are supplied by them. It also sells and licenses items all over the world, including the Pacific, Asia, Europe, Canada, the Americas, and the Middle East

Manufacturer usually replies in 9 days

colistimethate sodium

Powder for solution for injection/infusion 1 000 000 IU

Dossier type
CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Serbia , Vietnam
Manufacturer #3436

A pharmaceutical manufacturer based in the EU that has been active in 70+ countries selling its products in Europe, the Middle East, LATAM, North America, Africa, and Asia for 60+ years. Key production lines are Rx, OTC, and nutraceuticals. The company's production lines are EU GMP-compliant. Main therapeutic areas include the cardiovascular system, CNS, and dermatology. Main dosage forms include solid, topical, and suppositories.

Manufacturer usually replies in 20 days

colistimethate sodium

Vials, injection 1M IU, 2M IU, 150mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
European Union
Manufacturer #1187

colistimethate sodium

Vials, lyophilized injection 150 mg - 10 ml vial + 2 ml solvent ampoule

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP, PICS
Manufacturer #2760

Manufacturer usually replies in 5 days

colistimethate sodium

Vials, lyophilized injection 4500000 IU

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
EU GMP, PICS
Manufacturer #2272
The company integrates and applies enormous experience and technology in the field of hospital products. Their goal is to become a global leader in intensive care units and maintain that position. The company's headquarters were established in Europe in 1980ies, and serum production was continuing in a plant in Europe till the end of the 2000s. With a nationwide market share of 50%, it has become one of the leading serum producers. They've already started making the first ready-to-use injections.

Manufacturer usually replies in 7 days

colistimethate sodium

Solution for injection 1 000 000 IU, 2 000 000 IU, 3 000 000 IU, 150 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #2303

Manufacturer usually replies in 7 days

colistimethate sodium

Vials, injection 0.5 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Manufacturer #11531

Manufacturer usually replies in 6 days

colistimethate sodium

Ampoules, injection 1 000 000 IU

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
Argentina
Manufacturer #16247
The pharmaceutical company is currently in 120+ presentations corresponding to 50+ products that cover common clinical conditions, attended by a wide range of specialties. In Oncology and Special Treatments Line, which already has more than 3 products in more than 5 presentations, also venturing into the field of Pulmonology through a new Respiratory Line.

Manufacturer usually replies in 3 days

colistimethate sodium

Injection 1000000 IU

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20159

Manufacturer usually replies in 10 days

colistimethate sodium

Injection 1 MIU, 2 MIU, 3 MIU

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19203

Manufacturer usually replies in 6 days

colistimethate sodium

Injection 1MIU, 2MIU, 3MIU, 4.5MIU

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17417

Manufacturer usually replies in 6 days

colistimethate sodium

Solution for injection/infusion 1& 2 MIU

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17147

Manufacturer usually replies in 7 days

Want to view all 24 products? Create your free account today!

Colistimethate Sodium

Colistimethate Sodium is an antibiotic derived from bacteria of the genus Paenibacillus. It is the last- resort treatment for multidrug-resistant Gram-negative infections including pneumonia which includes infections caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, or Acinetobacter. Colistimethate Sodium is supplied in forms for injection into a vein or into a muscle, or inhaled, known as Colistimethate sodium and can also be applied to the skin or taken by mouth, known as colistin sulfate. Colistimethate Sodium is sold under the brand names Xylistin, Coly-Mycin M, Colobreathe among others. Koyama discovered polymyxins, initially in 1947, and Colistimethate Sodium as a secondary metabolite of the Gram-positive soil. It was approved for medical use in the United States in 1970. Due to its safety record and worldwide use, it features on the World Health Organization's List of Essential Medicines in addition to classifying Colistimethate Sodium as critically important for human medicine. Since the expiry of its initial patent protection, it is now made by several companies around the world as a generic medication.

Dosage Forms & Administration

Colistimethate Sodium is sold as a powder for injection in 150mg per vial. In the treatment of Susceptible Infections, the initial adult dose prescribed is 2.5-5 mg per kilo per day, spaced 6 to 12 hours apart. The daily maximum dose can not exceed 5 mg. this is followed by a Maintenance dose of 9MIU a day, administered in 2-3 divided doses and for critically ill patients, an initial loading dose of 9 MIU is prescribed.

The price of Colistimethate Sodium

In India, the consumers have to pay a retail price of USD 600 for a supply of 60 vials of generic brand of 1 MIU Colistimethate Sodium injection. This price is significantly higher in the developed world. In the USA, a generic brand supply of 60 vials of 150mg costs the consumer an average retail price of $2,883.38.

How does Colistimethate Sodium?

Colistimethate is an anti-biotic and also acts as a surface-active agent. It penetrates into and disrupts the bacterial cell membrane. Colistimethate has both hydrophobic and lipophilic moieties as a polycationic. It interacts and changes the permeability of the bacterial cytoplasmic membrane leading to the deal of bacteria cells.

Finding Colistimethate Sodium Manufacturers and Suppliers

The best way to find and gain access to Colistimethate Sodium manufacturers and Colistimethate Sodium suppliers are to make through Pipelinepharma's global B2B online marketplace for medicines and other pharmaceuticals. Normally, finding trusted manufacturers and supplies of specific drugs like Colistimethate Sodium can be a time-consuming challenge, but with Pipelinepharma's simple search engine and network of proven partners, the whole process becomes a lot easier. All you need to do to get started is to make use of our integrated search engine and start looking for suppliers or manufacturers of Colistimethate Sodium to work with. You can fine-tune your search results using various filters too, letting you search for Colistimethate Sodium from specific countries.